Blog

CAMBRIDGE, Mass. – November 10, 2021 – Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming investor conferences.

Caraway’s Chief Executive Officer, Martin D. Williams, will provide a company overview at the Jefferies 12^th Annual London Healthcare Conference on November 17, 2021, at 5:00 – 5:35 PM GMT (12:00 – 12:35 PM EST).

Williams will also present at the Piper Sandler 33^rd Annual Healthcare Conference taking place November 29 – December 2, 2021. A company presentation will be available to registered attendees via the conference website from November 22 to December 2, 2021.

“We have been focused on building a pipeline of oral small molecule therapeutics aimed at enhancing lysosomal function to activate the cell’s endogenous clearance and recycling processes for the treatment of neurodegenerative and rare diseases,” said Williams. “I look forward to providing updates on our promising programs at the Jefferies and Piper Sandler Healthcare conferences.”

 

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.

 

Media Contact:
MacDougall

Kari Watson or Nicholas Chang
(781) 235-3060

kwatson@macbiocom.com or nchang@macbiocom.com

 

 

CAMBRIDGE, Mass. – September 16, 2021 – Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Thursday, September 23, 2021 at 2:55pm Eastern Time. The presentation will cover recent progress from Caraway’s lead program targeting modulation of the lysosomal cation channel, TRPML1, for GBA-Parkinson’s disease and other rare diseases, and highlight the recently established collaboration with AbbVie on Caraway’s second program targeting the lysosomal potassium channel, TMEM175, for Parkinson’s and other neurodegenerative diseases.

“I look forward to sharing updates on Caraway’s promising programs at the Oppenheimer healthcare fall summit,” said Williams. “We have made substantial progress on our approach that combines genetically defined targets and our expertise in lysosomal biology to develop oral small molecule therapeutics to address unmet medical needs in neurodegenerative and rare diseases.”

 

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.

 

Media Contact:
MacDougall

Kari Watson or Nicholas Chang
(781) 235-3060

kwatson@macbiocom.com or nchang@macbiocom.com

 

 

CAMBRIDGE, MA –March 25, 2021 – Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming virtual investor events in April 2021.

Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel CNS Day on April 1, 2021 at 2:30pm ET and the Company is participating in the Needham Annual Healthcare Conference on April 13, 2021.

“I look forward to discussing the details of Caraway’s approach to developing treatments for genetically-defined neurodegenerative and rare diseases at Needham’s and Stifel’s upcoming events,” said Williams. “Our approach to creating oral small molecule therapeutics is informed by genetic data and our unique insights into lysosomal function, and I am pleased to have the opportunity to share our recent scientific progress.”

 

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.

Media Contact:
MacDougall

Caroline Rufo, PhD or Kari Watson
(781) 235-3060

crufo@macbiocom.com or kwatson@macbiocom.com

 

 

CAMBRIDGE, Mass. – January 25, 2021 – Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the Winter Private Company Showcase, co-hosted by Solebury Trout, Oppenheimer and White & Case on Friday, January 29, 2021 at 11am Eastern Time. The presentation will provide an overview of the Company’s unique approach to enhancing endogenous cellular clearance mechanisms as a therapeutic strategy for genetically defined neurodegenerative and rare diseases. Recent progress from Caraway’s TRPML1 and TMEM175 programs will be highlighted.

 

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.

Media Contact:
MacDougall

Caroline Rufo, PhD or Kari Watson
(781) 235-3060

crufo@macbiocom.com or kwatson@macbiocom.com

 

 

CAMBRIDGE, MA –November 18, 2020 – Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This latest grant builds on Caraway’s drug discovery research focused on the role of lysosomal function and autophagy in neurodegenerative and rare diseases to further investigate the role of TMEM175, a lysosomal ion channel genetically implicated in Parkinson’s disease (PD).

Recent genetic data from multiple studies indicate that variants in TMEM175 impact both age of onset and incidence of PD. Decreased TMEM175 function reduces lysosomal efficiency in neuronal cells, which is strongly associated with Parkinson’s disease. Furthermore, overexpression of TMEM175 reduces the pathology observed in neurons that occurs with synuclein exposure, potentially enhancing neuronal health. The Company will use the grant funding to further investigate the role of TMEM175 in cellular models of disease and evaluate the utility of TMEM175 agonists as therapeutics, and ultimately to develop a new class of PD therapeutics.

“Receiving this grant from The Michael J. Fox Foundation is extremely validating for our science, and we are honored to work with the organization,” said Martin D. Williams, Chief Executive Officer at Caraway Therapeutics. “Our unique drug discovery platform, electrophysiology capabilities and expertise in lysosomal function will allow us to rapidly advance this program towards the clinic.”

“Mutations in TMEM175 are clear risk factors for the development of Parkinson’s disease,” added Magdalene Moran, Chief Scientific Officer at Caraway Therapeutics. “Our approach is to activate this potassium channel to restore lysosomal function. Lysosomal dysfunction is emerging as a driver of PD pathology in both familial and idiopathic forms of disease. We believe that TMEM175 agonists could be an important way to alleviate this dysfunction.”

“Our Foundation funds research into emerging therapeutic options for people living with Parkinson’s today and for those who may be at risk of developing this disease. We are glad to support Caraway’s investigation of TMEM175 as a novel therapeutic target toward our goal of a world without Parkinson’s disease,” said Marco Baptista, MJFF Vice President of Research Programs.

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.

Media Contact:

MacDougall

Caroline Rufo, PhD or Kari Watson
(781) 235-3060

crufo@macbiocom.com or kwatson@macbiocom.com

 

 

 

CAMBRIDGE, MA –November 10, 2020 – Caraway Therapeutics today announced that the Company is scheduled to present at two upcoming virtual conferences during November, 2020.

Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 8:40am ET.

Caraway’s President and Chief Scientific Officer, Magdalene Moran, Ph.D., will present in two sessions at the Autophagy Showcase at the Drugging Autophagy Summit on November 19th. Dr. Moran will moderate and participate in the panel discussion titled, ‘How Much is Our Understanding of the Fundamental Biology Impacting the Druggability of Autophagy?’ on November 19, 2020 at 10:05am ET and will deliver a presentation titled, ‘Targeting TRPML1 for Neurodegenerative Disease’ on November 19, 2020 at 11:05am ET. For more information about the Drugging Autophagy Summit visit https://www.druggingautophagy.com/.

“At Caraway we are developing an approach to combine genetic data and our unique understanding of lysosomal function to discover small molecules that activate a cell’s clean-up and recycling processes thereby accelerating clearance of toxic materials and defective cellular components,” said Martin D. Williams, Chief Executive Officer of Caraway Therapeutics. “Magdalene and I are pleased to continue to showcase this targeted approach and the importance of modulating lysosomal function as a therapeutic strategy at the Stifel Banking Conference and Drugging Autophagy Summit.”

 

About Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically-defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.

 

Media Contact:
MacDougall
Caroline Rufo, PhD or Kari Watson
(781) 235-3060
crufo@macbiocom.com or kwatson@macbiocom.com